Biochronomer™ technology and the development of APF530, a sustained release formulation of granisetron

Granisetron and other 5-hydroxytryptamine type 3 (5-HT(3)) receptor antagonists are first-line agents for preventing chemotherapy-induced nausea and vomiting (CINV). Current treatment guidelines prefer the longer-acting agent, palonosetron, for CINV prevention in some chemotherapy regimens. A new gr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ottoboni, Thomas, Gelder, Mark S, O’Boyle, Erin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863535/
https://www.ncbi.nlm.nih.gov/pubmed/27186139
http://dx.doi.org/10.2147/JEP.S68880

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863535/
https://www.ncbi.nlm.nih.gov/pubmed/27186139
http://dx.doi.org/10.2147/JEP.S68880

Ejemplares similares